An FDA-approved, more refined cousin of Sermorelin that prompts your body's own growth-hormone release.
Reducing deep belly (visceral) fat and growth-hormone support.
Approved for a specific HIV-related condition; other uses extrapolate from that. Needs blood-sugar and IGF-1 monitoring.
What it is
Tesamorelin is a more refined, longer-acting version of the signal your hypothalamus naturally sends to tell your pituitary gland to produce growth hormone. Think of it as a more precise version of Sermorelin — the same general idea, but engineered to stay active in the body longer and produce a more predictable response. It's FDA-approved under the brand name Egrifta for a specific condition: deep belly fat that accumulates as a side effect of HIV antiretroviral therapy. In that context, clinical trials showed it reduced visceral fat by 15-20% as measured by CT scan. One important detail: the fat returns if you stop using it, so it requires ongoing treatment. Outside of that specific use, it's applied in functional medicine for body composition support — but that's an extrapolation from the HIV trial data, not its own separate evidence base.
Potential benefits
Visceral Fat Reduction — FDA-Approved Indication
Phase 3 RCT demonstrated significant visceral adipose tissue reduction vs. placebo in HIV lipodystrophy. CT-scan verified. Effect reverses on discontinuation.
GH Stimulation & IGF-1 Increase
Well-characterized pulsatile GH release with more predictable IGF-1 elevation than some secretagogues. IGF-1 elevation is part of the mechanism and a risk consideration.
Metabolic Markers
Trial data shows triglyceride improvements and some metabolic marker benefit in HIV population. Translation to non-HIV metabolic patients is plausible but not established in equivalent trials.
Cognitive Function (Emerging)
Small Phase 2 trials suggest improvements in processing speed and executive function in older adults and HIV patients with mild cognitive impairment. Emerging — not established indication.
Risks and contraindications
Side Effects (from FDA trials)
- Injection site reactions — common
- Peripheral edema — fluid retention
- Arthralgia (joint pain) · Myalgia
- Peripheral tingling / neuropathy
- Glucose elevation — explicitly noted in prescribing information
Serious Risks from Prescribing Information
- IGF-1 elevation + cancer risk: explicitly contraindicated in active malignancy
- Glucose intolerance / diabetes worsening: not recommended without monitoring
- Effect reversibility: visceral fat returns after discontinuation — ongoing treatment required
Contraindications / cautions
- Active malignancy — FDA prescribing contraindication
- Pregnancy · Pituitary tumors · Cranial radiation history
- Hypersensitivity to tesamorelin or mannitol
- Diabetes without glucose monitoring in place (caution)
- Sleep apnea · Stacking with other GH secretagogues (caution)
Research reality
A large, well-designed clinical trial confirmed significant visceral fat reduction in people with HIV-related lipodystrophy, verified by CT imaging. The FDA approved it on that basis in 2019. Smaller trials have looked at cognitive function benefits in older adults, with early promising results. Research in people without HIV-related conditions hasn't been done at the same scale.
Approved as Egrifta specifically for HIV-associated fat redistribution. Using it for general body composition goals in otherwise healthy people is common in functional medicine but represents an extrapolation from a specific disease population — worth understanding before you decide.
Better documented than most compounds here because of its FDA approval. The main monitoring requirements are non-negotiable: blood sugar and IGF-1 levels need to be checked at baseline and regularly throughout use. Using it without that monitoring removes the safety net the approval was built around.
Strong regulatory and clinical credibility. The approval is for a specific patient population — use for body composition in other people extrapolates from that data. One of the stronger GH-axis options, with a more predictable IGF-1 response. Glucose and IGF-1 monitoring are non-negotiable.